Literature DB >> 22425128

Changes in initial expenditures for benign prostatic hyperplasia evaluation in the Medicare population: a comparison to overall Medicare inflation.

Adam S Bellinger1, Sean P Elliott, Liu Yang, John T Wei, Christopher S Saigal, Alexandria Smith, Timothy J Wilt, Seth A Strope.   

Abstract

PURPOSE: Benign prostatic hyperplasia creates significant expenses for the Medicare program. We determined expenditure trends for benign prostatic hyperplasia evaluative testing after urologist consultation and placed these trends in the context of overall Medicare expenditures.
MATERIALS AND METHODS: Using a 5% national sample of Medicare beneficiaries from 2000 to 2007 we developed a cohort of 40,253 with claims for new visits to urologists for diagnoses consistent with symptomatic benign prostatic hyperplasia. We assessed trends in initial inflation and geography adjusted expenditures within 12 months of diagnosis by evaluative test categories derived from the 2003 American Urological Association guideline on the management of benign prostatic hyperplasia. Using governmental reports on Medicare expenditure trends for benign prostatic hyperplasia we compared expenditures to overall and imaging specific Medicare expenditures. Comparisons were assessed by the Z-test and regression analysis for linear trends, as appropriate.
RESULTS: Between 2000 and 2007 inflation adjusted total Medicare expenditures per patient for the initial evaluation of patients with benign prostatic hyperplasia seen by urologists increased from $255.44 to $343.98 (p <0.0001). Benign prostatic hyperplasia related imaging increases were significantly less than overall Medicare imaging expenditure increases (55% vs 104%, p <0.001). The increase in per patient expenditures for benign prostatic hyperplasia was significantly lower than the increase in overall Medicare expenditures per enrollee (35% vs 45%, p = 0.0015).
CONCLUSIONS: From 2000 to 2007 inflation adjusted expenditures increased for benign prostatic hyperplasia related evaluations. This growth was slower than the overall growth in Medicare expenditures. The increase in BPH related imaging expenditures was restrained compared to that of the Medicare program as a whole.
Copyright © 2012 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22425128      PMCID: PMC3539409          DOI: 10.1016/j.juro.2011.12.079

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  18 in total

1.  Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.

Authors:  Joan L Warren; Carrie N Klabunde; Deborah Schrag; Peter B Bach; Gerald F Riley
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

2.  The quality of health care delivered to adults in the United States.

Authors:  Elizabeth A McGlynn; Steven M Asch; John Adams; Joan Keesey; Jennifer Hicks; Alison DeCristofaro; Eve A Kerr
Journal:  N Engl J Med       Date:  2003-06-26       Impact factor: 91.245

Review 3.  Computed tomography--an increasing source of radiation exposure.

Authors:  David J Brenner; Eric J Hall
Journal:  N Engl J Med       Date:  2007-11-29       Impact factor: 91.245

4.  Update on AUA guideline on the management of benign prostatic hyperplasia.

Authors:  Kevin T McVary; Claus G Roehrborn; Andrew L Avins; Michael J Barry; Reginald C Bruskewitz; Robert F Donnell; Harris E Foster; Chris M Gonzalez; Steven A Kaplan; David F Penson; James C Ulchaker; John T Wei
Journal:  J Urol       Date:  2011-03-21       Impact factor: 7.450

5.  Urologist compliance with AUA best practice guidelines for benign prostatic hyperplasia in Medicare population.

Authors:  Seth A Strope; Sean P Elliott; Christopher S Saigal; Alex Smith; Timothy J Wilt; John T Wei
Journal:  Urology       Date:  2011-05-23       Impact factor: 2.649

6.  Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia.

Authors:  Steven A Kaplan; Konstantin Walmsley; Alexis E Te
Journal:  J Urol       Date:  2005-12       Impact factor: 7.450

7.  Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention.

Authors:  William B Borden; Rita F Redberg; Alvin I Mushlin; David Dai; Lisa A Kaltenbach; John A Spertus
Journal:  JAMA       Date:  2011-05-11       Impact factor: 56.272

Review 8.  Benign prostatic hyperplasia in primary care: what you need to know.

Authors:  Arthur L Burnett; Alan J Wein
Journal:  J Urol       Date:  2006-03       Impact factor: 7.450

9.  Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.

Authors:  Steven A Kaplan; Claus G Roehrborn; Eric S Rovner; Martin Carlsson; Tamara Bavendam; Zhonghong Guan
Journal:  JAMA       Date:  2006-11-15       Impact factor: 56.272

10.  Urologic diseases in America project: benign prostatic hyperplasia.

Authors:  John T Wei; Elizabeth Calhoun; Steven J Jacobsen
Journal:  J Urol       Date:  2005-04       Impact factor: 7.450

View more
  3 in total

1.  Cost of illness of medically treated benign prostatic hyperplasia in Hungary.

Authors:  Fanni Rencz; Ágnes Kovács; Valentin Brodszky; László Gulácsi; Zalán Németh; Gábor János Nagy; János Nagy; István Buzogány; Géza Böszörményi-Nagy; Attila Majoros; Péter Nyirády
Journal:  Int Urol Nephrol       Date:  2015-06-21       Impact factor: 2.370

2.  2-Methoxyestradiol Attenuates Testosterone-Induced Benign Prostate Hyperplasia in Rats through Inhibition of HIF-1α/TGF-β/Smad2 Axis.

Authors:  Ashraf B Abdel-Naim; Thikryat Neamatallah; Basma G Eid; Ahmed Esmat; Abdulmohsin J Alamoudi; Gamal S Abd El-Aziz; Osama M Ashour
Journal:  Oxid Med Cell Longev       Date:  2018-08-01       Impact factor: 6.543

3.  Cordycepin Attenuates Testosterone-Induced Benign Prostatic Hyperplasia in Rats via Modulation of AMPK and AKT Activation.

Authors:  Abdulmohsin J Alamoudi; Sami A Alessi; Waleed Y Rizg; Abdulmajeed M Jali; Awaji Y Safhi; Fahad Y Sabei; Sameer Alshehri; Khaled M Hosny; Ashraf B Abdel-Naim
Journal:  Pharmaceutics       Date:  2022-08-08       Impact factor: 6.525

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.